DEA Permanently Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I

The Drug Enforcement Administration has issued a final rule permanently adding CUMYL-PEGACLONE to Schedule I of the Controlled Substances Act. Schedule I is the highest level of control, meaning the agency considers the substance to have a high potential for abuse and no currently accepted medical use. The rule also covers any salts, isomers, or related chemical forms of the drug.

Why it matters: This rule closes a regulatory gap by turning a temporary restriction into a permanent one. It ensures federal law matches the United States’ treaty obligations and gives law enforcement and prosecutors a clear legal basis to charge possession, distribution, or manufacturing of the substance. For researchers or manufacturers who had been working with it under the temporary order, the rule means they must now obtain specific DEA registration and follow strict handling protocols, or stop using it entirely.

Who it affects

• Manufacturers, distributors, and sellers of synthetic cannabinoids or related chemical compounds

---

This final rule was issued by the Drug Enforcement Administration and published in the Federal Register; you should verify the exact chemical definitions and compliance deadlines in the original document before adjusting business or research operations.

Agency: Justice Department, Drug Enforcement Administration
Source: Federal Register — read the official document